標(biāo)題: Titlebook: Glutamate and Neuropsychiatric Disorders; Current and Emerging Zoran M. Pavlovic Book 2022 Springer Nature Switzerland AG 2022 Aggression.A [打印本頁(yè)] 作者: TIBIA 時(shí)間: 2025-3-21 17:15
書目名稱Glutamate and Neuropsychiatric Disorders影響因子(影響力)
書目名稱Glutamate and Neuropsychiatric Disorders影響因子(影響力)學(xué)科排名
書目名稱Glutamate and Neuropsychiatric Disorders網(wǎng)絡(luò)公開度
書目名稱Glutamate and Neuropsychiatric Disorders網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Glutamate and Neuropsychiatric Disorders被引頻次
書目名稱Glutamate and Neuropsychiatric Disorders被引頻次學(xué)科排名
書目名稱Glutamate and Neuropsychiatric Disorders年度引用
書目名稱Glutamate and Neuropsychiatric Disorders年度引用學(xué)科排名
書目名稱Glutamate and Neuropsychiatric Disorders讀者反饋
書目名稱Glutamate and Neuropsychiatric Disorders讀者反饋學(xué)科排名
作者: circumvent 時(shí)間: 2025-3-21 23:49
,Wege in die ?Neolithische Revolution“,ity, reducing our quality of life, and increasing our medical expenditures exponentially. Although a certain amount of stress is positive and beneficial for performance, such as “eustress,” chronic stress experienced for an extended time overwhelms the body’s coping mechanisms. We begin our chapter 作者: 有發(fā)明天才 時(shí)間: 2025-3-22 04:09
Gebiets- und Individualeffekte,ological diseases, including Depression, Schizophrenia, and Neurodegenerative Disorders. The following sections present the impact of chronic stress on the glutamatergic system, ionotropic and metabotropic glutamate receptors, and excitatory amino acid transporters. The chapter continues with a desc作者: 雪崩 時(shí)間: 2025-3-22 07:44
https://doi.org/10.1007/978-3-476-03530-1sion in adults and its quick introduction in everyday psychiatric practice might be considered as a second revolution in the field of neuropsychopharmacology after the first one, which started over 50 years ago with the discovery of the monoaminergic antidepressants. This chapter will present the cr作者: NAUT 時(shí)間: 2025-3-22 12:02 作者: 清楚說(shuō)話 時(shí)間: 2025-3-22 15:14 作者: 清楚說(shuō)話 時(shí)間: 2025-3-22 18:20 作者: 考得 時(shí)間: 2025-3-22 21:22 作者: 現(xiàn)存 時(shí)間: 2025-3-23 02:10
Hilde Weiss,Moujan Wittmann-Roumi Rassoulimal models help to clarify the neurocircuitry of both defensive and predatory aggression. Together with other neurotransmitters, glutamate is involved in the medial amygdala–mediobasal hypothalamus–dorsal periaqueductal gray pathway which triggers defensive aggression in animal models and impulsive 作者: 期滿 時(shí)間: 2025-3-23 08:13 作者: PRE 時(shí)間: 2025-3-23 10:29 作者: 等待 時(shí)間: 2025-3-23 13:58 作者: 填滿 時(shí)間: 2025-3-23 19:10
https://doi.org/10.1007/978-3-662-55990-1ion. As such, there is great interest in identifying optimal treatment options which beneficially reduce pain with limited side effects. Potential options include antagonism of ionotropic and Group I metabotropic glutamate (mGlu) receptors, agonism of Group II and III mGlu receptors, modulation of t作者: CLAIM 時(shí)間: 2025-3-24 01:40 作者: ETHER 時(shí)間: 2025-3-24 02:31
Einleitung: Fragestellung und Studiendesign,ous system (CNS). Besides these signs, a diffuse loss of synaptic contacts, axonal pruning and astrocytosis are also observed, that in general correlate with the dysregulation of the glutamatergic system and with the onset of neurological symptoms. Concomitantly to the synaptic derangements, impaire作者: wangle 時(shí)間: 2025-3-24 07:16 作者: Pedagogy 時(shí)間: 2025-3-24 11:28
https://doi.org/10.1007/978-3-658-17617-4logy of schizophrenia. Genetic, postmortem and neuroimaging studies in schizophrenia patients showed alterations in different glutamatergic elements. Thus, glutamatergic system has emerged as a promising target for the treatment of schizophrenia, especially for symptoms not addressed by current anti作者: 搬運(yùn)工 時(shí)間: 2025-3-24 18:54
Leben mit der koronaren Herzkrankheitalance can induce neuronal hyper-excitability in a susceptible neuronal network leading to seizures. Glutamate is the main excitatory neurotransmitter in the nervous system but when it is accumulated in excess induces neurotoxicity, mediates neuronal hyper-excitability and seizures. In epilepsy, glu作者: 單片眼鏡 時(shí)間: 2025-3-24 21:43 作者: 吞下 時(shí)間: 2025-3-25 00:17 作者: ERUPT 時(shí)間: 2025-3-25 05:34 作者: 標(biāo)準(zhǔn) 時(shí)間: 2025-3-25 11:28 作者: 善于 時(shí)間: 2025-3-25 14:25
Current Glutamatergic Treatments and Future Directions for Glutamate-Based Management of Chronic Stsion in adults and its quick introduction in everyday psychiatric practice might be considered as a second revolution in the field of neuropsychopharmacology after the first one, which started over 50 years ago with the discovery of the monoaminergic antidepressants. This chapter will present the cr作者: Affirm 時(shí)間: 2025-3-25 18:28
The Role of the Glutamate System in Posttraumatic Stress Disorder and Glutamate-Based Treatments,dance, hyperarousal, emotional numbing, and anhedonia. PTSD is often triggered by exposure to a single traumatic experience, with high prevalence among war veterans. PTSD, together with other neuropsychiatric disorders, involves long-term changes in the structure and function of brain areas, synapti作者: Costume 時(shí)間: 2025-3-25 22:02 作者: 單調(diào)性 時(shí)間: 2025-3-26 03:30 作者: 信任 時(shí)間: 2025-3-26 04:44
The Glutamatergic System as a Target for the Development of New Pharmacological Treatments of Bipolabilizers used to treat it are not always sufficient for all patients and typically depression in patients with bipolar disorder (BD) is not well responding to antidepressants. Glutamate is the major excitatory neurotransmitter of the CNS and is present in more than 50% of nerve tissue. The relation作者: Repatriate 時(shí)間: 2025-3-26 12:15 作者: CLAP 時(shí)間: 2025-3-26 16:34
,Glutamatergic Treatments for Parkinson’s Disease,n-motor symptoms. The current knowledge demonstrates that the activity of glutamatergic signals from the cortex to the striatum is strictly regulated during the progression of the disease and indicates that modulation of synaptic transmission at the glutamatergic synapse represents a major target to作者: 兩棲動(dòng)物 時(shí)間: 2025-3-26 20:29
The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression, a potential therapeutic strategy for Major Depressive Disorder (MDD), from animal models to recent phase III clinical trials. The main clinical features of MDD, its epidemiological impact in terms of disease burden, its mainstream pharmacological treatment, and current unmet needs are presented. A 作者: Patrimony 時(shí)間: 2025-3-26 22:25
Glutamate-Based Treatment for Amyotrophic Lateral Sclerosis/Motor Neuron Disease,n, synaptic plasticity, learning and memory consolidation, arousal, and behavior. Upon certain circumstances, the glutamate homeostasis can be severely affected by the overproduction of this excitatory neurotransmitter, ultimately leading to neurodegenerative events via excitotoxic mechanisms. There作者: Decrepit 時(shí)間: 2025-3-27 02:02 作者: 音樂(lè)學(xué)者 時(shí)間: 2025-3-27 08:07
Pharmacological Role of Glutamate Transporters in Substance Use Disorders,diction requires the identification of targetable neurobiological mechanisms. As the primary excitatory neurotransmitter in the brain glutamate possesses a significant role in plasticity, learning, and memory, and represents a promising neurotransmitter of focus for intervention in the etiology of S作者: mastoid-bone 時(shí)間: 2025-3-27 12:36 作者: 控制 時(shí)間: 2025-3-27 16:44
The Role of Glutamate Dysregulation in the Etiology of ADHD,s are briefly discussed. The glutamate system in general and its potential role in ADHD are thoroughly reviewed evaluating both preclinical and clinical data. The current ADHD treatments that act on the glutamate system, memantine and atomoxetine, are discussed. The chapter concludes with a discussi作者: 分開如此和諧 時(shí)間: 2025-3-27 21:13
Glutamate, Glutamatergic Drugs and Schizophrenia,logy of schizophrenia. Genetic, postmortem and neuroimaging studies in schizophrenia patients showed alterations in different glutamatergic elements. Thus, glutamatergic system has emerged as a promising target for the treatment of schizophrenia, especially for symptoms not addressed by current anti作者: 烤架 時(shí)間: 2025-3-27 23:55 作者: 軟膏 時(shí)間: 2025-3-28 06:06
Glutamate Function in Anxiety Disorders and OCD: Evidence from Clinical and Translational Studies,ering and disabilities on the people affected. Among the anxiety disorders described in DSM-5, the most prevalent and studied are generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder (PD). Obsessive-compulsive disorder (OCD), although it shares many morphophysiopatho作者: –吃 時(shí)間: 2025-3-28 08:15 作者: Oscillate 時(shí)間: 2025-3-28 12:11 作者: 宿醉 時(shí)間: 2025-3-28 16:05
Zoran M. PavlovicReviews the interplay of the glutamatergic system with other neurotransmitters & neurotrophic factors in CNS diseases.Individual chapters deal with the neuropathophysiology and glutamate-based treatme作者: 異常 時(shí)間: 2025-3-28 20:13
https://doi.org/10.1007/978-3-658-32451-3 in extracellular glutamate, which induces pathogenic mechanisms, leading to neuroexcitotoxicity. In order to mitigate the deleterious effects of excitotoxicity, neuroprotective drugs have been developed to block the postsynaptic and presynaptic receptors of glutamate. These treatments have not show作者: gentle 時(shí)間: 2025-3-29 02:42 作者: creatine-kinase 時(shí)間: 2025-3-29 04:47
Gebiets- und Individualeffekte,ion is dedicated to the impact of chronic stress on gene expression and epigenetic modifications in glutamatergic neuronal networks, followed by the part on stress-induced glutamate effects leading to oxidative and nitrosative neuronal stress and excitotoxicity. We conclude the chapter with the late作者: Stagger 時(shí)間: 2025-3-29 11:16
https://doi.org/10.1007/978-3-476-03530-1 have been suggested to underlie the fast antidepressant properties of Ketamine. Alternative investigational therapeutic uses of Ketamine (besides as an antidepressant) will then be presented, followed by the description of other glutamatergic drugs which received significant attention for their pot作者: aviator 時(shí)間: 2025-3-29 12:56
https://doi.org/10.1007/978-3-322-95544-9ears a major shift in the conceptual framework of neuropsychiatric disorders has occurred, from the monoamine hypothesis to a neuroplasticity hypothesis, in which the glutamate system is conceived as a primary mediator of pathology and a straight target for antidepressant drugs. Novel potential trea作者: 銀版照相 時(shí)間: 2025-3-29 17:23
https://doi.org/10.1007/978-3-476-98856-0ine to chronic migraine. Some of the current migraine treatments include in their mechanism of action, at least partly, modulation of glutamatergic signalling. While some attempts have been made to directly block glutamate receptors, these were abandoned due to the development of significant side ef作者: Overthrow 時(shí)間: 2025-3-29 21:48
Ralf G. Herrtwich,Wieland Holfelderinical trials, synaptic glutamate signaling and EAAT2, I argue why EAAT2 drugs make therapeutic sense, and then describe a simple drug screening assay how to find them, by targeting the EAAT2 protein reconstituted in liposomes.作者: MAIM 時(shí)間: 2025-3-30 03:34
Leben in der multikulturellen Gesellschaftlogy of mood disorders is expected to complement and improve the prevailing monoamine hypothesis and may indicate novel therapeutic targets. There are currently few pharmacological agents that act on the glutamatergic system and have been approved for the treatment of bipolar disorder. In fact, only作者: 一再遛 時(shí)間: 2025-3-30 06:24
,Ab ins Büro! Die Stechuhr ruft!,n preclinical and clinical studies. At present, amantadine, a low-affinity non-competitive NMDA receptor antagonist, represents a recommended add-on agent to decrease the dyskinetic motor complications of the dopaminergic therapy..The chapter will describe advances in basic research, preclinical and作者: Phenothiazines 時(shí)間: 2025-3-30 10:44
https://doi.org/10.1007/978-3-662-58267-1tentiation, mammalian target of the rapamycin complex 1 (mTORC1) modulation and GABA-A receptor modulation. The current modulators of the glutamatergic signaling for the treatment of MDD are presented: intravenous ketamine (off-label use for MDD), intranasal esketamine (FDA approved for TRD), and in作者: 遠(yuǎn)足 時(shí)間: 2025-3-30 13:24
https://doi.org/10.1007/b137843 neuron dysregulation consistent with the degeneration of pyramidal neurons in the motor cortex, cranial motor neurons, and anterior horn cells in the spinal cord. This chapter aims at offering an overview of impaired molecules of the glutamatergic system in ALS/MND pathology. A relevant part of the作者: Blatant 時(shí)間: 2025-3-30 18:42
https://doi.org/10.1007/978-3-662-55990-1 intervention may be good adjunct treatments due to the positive effects on glutamatergic neurotransmission and reduction of inflammation, with little to no side effects. Current pharmacological and non-pharmacological treatment options which affect glutamatergic neurotransmission for the treatment 作者: allergy 時(shí)間: 2025-3-30 22:31 作者: 武器 時(shí)間: 2025-3-31 03:42 作者: Vasoconstrictor 時(shí)間: 2025-3-31 06:11
https://doi.org/10.1007/978-3-658-17617-4at the glycine-binding site and inhibition of the glycine transporter (GlyT1). Additionally, agonists of the mGlu2/3 receptor and positive allosteric modulators (PAMs) of mGlu2 receptors have been tested as therapeutic bets for the treatment of schizophrenia. From all emerging glutamatergic drugs in作者: preservative 時(shí)間: 2025-3-31 12:26
Leben mit der koronaren Herzkrankheits) in neurons. In addition, the abnormal molecular signaling from those receptors promotes cell damage and aberrant neuronal plasticity that could participate in the biology mechanism of epilepsy. In addition, glutamate is accumulated in other neurological with high incidence of recurrent epilepsy, 作者: 失望昨天 時(shí)間: 2025-3-31 16:03
Der Auswertungsprozess der Studiel axis (HPA) is addressed. Studies on the role of glutamate in disorders are considered, as well as the brain structures involved. The cortico-striated-thalamus-cortical (CSTC) and limbic areas connected to the circuit and involved in the OCD are addressed, highlighting the function of glutamate in 作者: AVANT 時(shí)間: 2025-3-31 19:05 作者: Chandelier 時(shí)間: 2025-4-1 00:14
Treatments Against Glutamatergic Excitotoxicity in Ischemic Stroke, in extracellular glutamate, which induces pathogenic mechanisms, leading to neuroexcitotoxicity. In order to mitigate the deleterious effects of excitotoxicity, neuroprotective drugs have been developed to block the postsynaptic and presynaptic receptors of glutamate. These treatments have not show作者: Tidious 時(shí)間: 2025-4-1 02:28 作者: Overdose 時(shí)間: 2025-4-1 08:17 作者: 廣告 時(shí)間: 2025-4-1 12:15
Current Glutamatergic Treatments and Future Directions for Glutamate-Based Management of Chronic St have been suggested to underlie the fast antidepressant properties of Ketamine. Alternative investigational therapeutic uses of Ketamine (besides as an antidepressant) will then be presented, followed by the description of other glutamatergic drugs which received significant attention for their pot作者: 托人看管 時(shí)間: 2025-4-1 16:35
The Role of the Glutamate System in Posttraumatic Stress Disorder and Glutamate-Based Treatments,ears a major shift in the conceptual framework of neuropsychiatric disorders has occurred, from the monoamine hypothesis to a neuroplasticity hypothesis, in which the glutamate system is conceived as a primary mediator of pathology and a straight target for antidepressant drugs. Novel potential trea作者: 單獨(dú) 時(shí)間: 2025-4-1 22:01
Glutamate in Migraine Neurobiology and Treatment,ine to chronic migraine. Some of the current migraine treatments include in their mechanism of action, at least partly, modulation of glutamatergic signalling. While some attempts have been made to directly block glutamate receptors, these were abandoned due to the development of significant side ef作者: 極肥胖 時(shí)間: 2025-4-2 00:55
Astrocyte Glutamate Transporter EAAT2 in Alzheimer Dementia,inical trials, synaptic glutamate signaling and EAAT2, I argue why EAAT2 drugs make therapeutic sense, and then describe a simple drug screening assay how to find them, by targeting the EAAT2 protein reconstituted in liposomes.
